Drug Digest: Focusing on Solid Dosage Trends and Demand

In this exclusive Drug Digest video interview, Felicity Thomas, Associate Editorial Director, Pharmaceutical Technology Group, interviews Dr. Ali Rajabi-Siahboomi from Colorcon about solid dosage drug development and manufacturing. During the discussion, Dr. Ali will provide an overview of the solid dosage drug development and manufacturing sector, factors driving growth in the market, challenges facing companies and the shifts in demand, the evolution of coating design, and regulatory considerations impacting oral solid dosage development and manufacturing.

Interview featuring

Dr. Ali Rajabi-Siahboomi

Ali Rajabi-Siahboomi is the vice president and chief innovation officer at Colorcon, based at the Global Headquarter, USA. Rajabi-Siahboomi has held various academic positions in Nottingham and Liverpool JM Universities in the UK before joining Colorcon as technical director, responsible for Europe, the Middle East, and Africa in 2000. His main research interests are solid dosage form pharmaceutics, pharmaceutical technology with emphasis on oral drug delivery systems, solubility enhancement to improve bioavailability, and consistency of drugs and bioequivalence formulations. He has published more than 300 articles, book chapters, abstracts, and patents and obtained his B.Pharm. and PhD in pharmacy from the University of Nottingham (UK).

Sponsors

This episode of Drug Digest is sponsored by:

• Adare Pharma Solutions
• Catalent
• Clariant
• LabVantage Solutions
• LGM Pharma

About Drug Digest

Drug Digest is a tech talk video series with the Pharmaceutical Technology® editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.

Upcoming episodes

• December 2024: Emerging Therapies and Targeted Delivery
• January 2025: Advances in Small-Molecule Manufacturing
• March 2025: Strategic Partnership Updates